I went back and looked at the notes and conversation I had with Hargrove, he never said that he didn't look at the scorecard, to correct this he stated that some of the retail investors that are in the stock only look at the scorecard, so I wanted to correct that statement. He wants to get more institutional investors involved something we have all heard before.
He said they are going from 10,000 - 20,000 gallbladder's cases to 4,000,000 by looking at all abdominal procedures, they will develop more advanced instrumentation, more advanced training as well as a complex matrix and these cases would not be considered off label as the regulatory communality is cracking down on it.
He said that if a hospital system has 3 locations in one area they can buy a sport and literally put it on rotation and move it from hospital to hospital by just bringing it down thru the elevator due to it mobility. That's a cost saving as they would only have to buy one.
I don't have the details that he mentioned about the possibilities of using 2 SPORTS on one procedure that may be something down the road and I apologize for this, during this conversation the stock was all over the place and I was pleasantly surprised that I got the call from the chairman but it was mentioned by him and previously one this board by another poster.
I've been in the market for many years and I believe this will be a winner. Haven't sold one share and have been adding over last and this week.
News 
Market Data 
Discover 
AI
